RagD auto-activating mutations impair MiT/TFE activity in kidney tubulopathy and cardiomyopathy syndrome

RagD自身激活突变会损害肾小管病和心肌病综合征中的MiT/TFE活性

阅读:3
作者:Irene Sambri # ,Marco Ferniani # ,Giulia Campostrini ,Marialuisa Testa ,Viviana Meraviglia ,Mariana E G de Araujo ,Ladislav Dokládal ,Claudia Vilardo ,Jlenia Monfregola ,Nicolina Zampelli ,Francesca Del Vecchio Blanco ,Annalaura Torella ,Carolina Ruosi ,Simona Fecarotta ,Giancarlo Parenti ,Leopoldo Staiano ,Milena Bellin ,Lukas A Huber ,Claudio De Virgilio ,Francesco Trepiccione ,Vincenzo Nigro ,Andrea Ballabio

Abstract

Heterozygous mutations in the gene encoding RagD GTPase were shown to cause a novel autosomal dominant condition characterized by kidney tubulopathy and cardiomyopathy. We previously demonstrated that RagD, and its paralogue RagC, mediate a non-canonical mTORC1 signaling pathway that inhibits the activity of TFEB and TFE3, transcription factors of the MiT/TFE family and master regulators of lysosomal biogenesis and autophagy. Here we show that RagD mutations causing kidney tubulopathy and cardiomyopathy are "auto- activating", even in the absence of Folliculin, the GAP responsible for RagC/D activation, and cause constitutive phosphorylation of TFEB and TFE3 by mTORC1, without affecting the phosphorylation of "canonical" mTORC1 substrates, such as S6K. By using HeLa and HK-2 cell lines, human induced pluripotent stem cell-derived cardiomyocytes and patient-derived primary fibroblasts, we show that RRAGD auto-activating mutations lead to inhibition of TFEB and TFE3 nuclear translocation and transcriptional activity, which impairs the response to lysosomal and mitochondrial injury. These data suggest that inhibition of MiT/TFE factors plays a key role in kidney tubulopathy and cardiomyopathy syndrome.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。